MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS
Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road,

Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 31580

Fax: 00 91 (22) 2202 4657 E-mail: info@amphray.com

Website: www.triochemproducts.com Corporate Identity Number: L24249MH1972PLC015544

Ref No: TPL PP 2021933 2021; 13th November 2021

To

BSE Limited

Corporate Relationship Department,

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Outcome of the Board - Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015

Pursuant to Notice of Board meeting dated 28th October, 2021 the Board meeting was held on today Saturday, 13th November, 2021 at 2.00 p.m. at 4th Floor, Sambava Chambers, Sir P. M. Road, Fort, Mumbai: 400001 and has approved the following:

- The Board approved the Unaudited Financial Results for the quarter and half year ended on 30th September 2021, as reviewed by the Audit Committee along with Statement of Assets and Liabilities as at September 30, 2021 and Cash Flow Statement for the half year ended September 30, 2021, in accordance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
- 2. The Board noted and took on records the Limited Review Report for the quarter and half year ended on 30th September 2021 as placed before the Board.
- 3. Take notes on the compliance for the quarter and half year ended 30th September 2021
- 4. Board Meeting commenced at 2.00 p.m. and concluded at 2.45 p.m.

You are requested to take note of the same.

Thanking you,

Yours faithfully,

For TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA

DIRECTOR

DIN: 00312369

Place: Mumbai

Mumbai

Chartered Accountants

Mumbai Address: 203, The Summit, Hanuman Road, Western Express Highway, Vile Parle (E), Mumbai - 400 057 T: 022-2615 0100 / 111 / 112 • F: 022 2615 0113

Pune Address: 123, Sohrab Hall, 21 Sassoon Road, Opp. Jehangir Hospital, Pune - 411001 • T: 020 4906 7177

E: info@kdg.co.in • W: www.kdg.co.in

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

The Board of Directors of TRIOCHEM PRODUCTS LIMITED ("Company")

- We have reviewed the accompanying statement of unaudited financial results of TRIOCHEM PRODUCTS LIMITED ("Company") for the quarter and half year ended September 30, 2021 being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by SEBI from time to time.
- 2. The statement is the responsibility of the Company's management and has been approved by Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind As 34"), specified under Section 133 of the Companies Act, 2013, SEBI Circular CIR/CFD/PAC/62/2016 dated 5 July 2016 (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India.
- We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Kanu Doshi Associates LLP Chartered Accountants

Firm Registration No: 104746W/W100096

KUNAL SUMANTBHAI SUMANTBHAI VAKHARIA VAKHARIA Date: 2021.11.13 14:44:49 +05'30

Kunal Vakharia

Partner

Membership No.: 148916 UDIN: 21148916AAAAJC6115

Place: Mumbai

Date: 13th November 2021



MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chamber, 4th Floor, Sir P M Road, Fort, Mumbai - 400 001.

Website: www.triochemproducts.com CIN: L24249MH1972PLC015544

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2021

	(Rs in Lakh) Except El						
Sr.	Particulars	Quarter Ended			Half Yea	Year Ended	
No.		30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	31-Mar-21
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from Operations	326.27	-	225.86	326.27	225.86	1,393.84
	(b) Other Income	11.00	18.19	4.38	29.19	5.68	13.38
	Total Income From Operations	337.27	18.19	230.24	355.46	231.54	1,407.22
	Expenses						
	(a) Cost of Materials Consumed		-	226.06		644.54	644.87
	(b) Purchase of stock in trade	549.75			549.75		602.73
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(274.87)		(47.76)	(274.87)	(472.07)	13.41
	(d) Employees Benefit Expenses	12.78	11.50	16.89	24.28	33.78	66.91
	(e) Finance Costs	1.14	0.38	4.97	1.52	7.06	10.90
	(f) Depreciation and Amortisation Expenses	2.99	2.95	3.46	5.94	6.88	13.88
	(g) Other Expenditure	17.82	18.56	33.79	36.38	53.83	112.64
	Total expenses	309.61	33.39	237.41	343.00	274.02	1,465.33
3	Profit before exceptional items and tax	27.66	(15.21)	(7.16)	12.46	(42.47)	(58.11
4	Exceptional items						
5	Profit/ (Loss) before tax	27.66	(15.21)	(7.16)	12.46	(42.47)	(58.11
6	Tax Expense						
	(a) Current tax		(0.22)	(0.00)	(0.22)	0.02	(0.75
	(b) Deferred tax	7.30	(4.06)		3.24	(10.56)	(12.66
	Total tax expenses	7.30	(4.28)			(10.54)	(13.41
	Net Profit/ (Loss) for the period	20.36	(10.93)			(31.93)	(44.70
8	Other Comprehensive Income (Net of Taxes)						
	(A)(i). Items that will be reclassified to profit or loss						
	(ii). Income tax relating to items that will be reclassified to						
	(B)(i). Item that will not be reclassified to profit or loss	(0.36)	1.68	(1.06)	1.32	(0.95)	(2.34
	(ii). Income tax relating to items that will not be reclassified to profit or loss	0.09	(0.42)		(0.33)	0.24	0.59
	Total other Comprehensive Income (net of taxes)	(0.27)	1.26	(0.79)	0.99	(0.71)	(1.75
9	Total Comprehensive Income for the period	20.09	(9.67)			(32.64)	
10	Paid-up equity share capital (Face Value of ₹ 10/- per share)	24.50		24.50	24.50	24.50	24.50
11	Other equity as per Balance Sheet of previous accounting year						1,146.69
12	Earnings per equity share (EPS) (of Rs. 10/- each) (not annualise	(d)					
	Basic / Diluted EPS (in Rs.)	8.31	(4.46)	(2.22)	3.85	(13.03)	(18.25







MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

_	STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPT Particulars	As at	As at
	Particulars		31-Mar-21
		30-Sep-21	
_		(Unaudited)	(Audited)
A	ASSETS		
1	Non- Current Assets		06.20
	(a) Property, plant and equipment	80.64	86.39
	(b) Capital work - in - progress	3.24	3.24
	(c) Investment property	7.53	7.72
	(d) Financial assets		
	(i) Other financial assets	7.32	7.32
	(e) Deferred tax assets (Net)	0.35	3.92
	(f) Other non current tax assets	0.71	0.7
	(g) Other non current assets	0.98	0.87
	Sub Total - Non- Current Assets	100.77	110.1
2	Current Assets		
	(a) Inventories	360.22	85.30
	(b) Financial Assets		
	(i) Trade receivable	365.45	139.0
	(ii) Cash and cash equivalents	299.42	819.7
	(iii) Other financial assets	0.15	0.69
	(c) Other tax assets (net)	49.73	33.1
	(d) Other current assets	44.26	22.0
	Sub Total - Current Assets	1,119.23	1,100.0
	TOTAL ASSETS	1,220.00	1,210.20
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	24.50	24.5
	(b) Other equity	1,157.12	1,146.6
	Sub Total - Shareholder's fund	1,181.62	1,171.19
-	Liabilities		
	(a) Non Current Liabilities		
	(a) Deferred tax liabilities (Net)		
	(b) Current Liabilities		
	(a) Financial liabilities	1	
	(i) Borrowing		
	(ii) Trade payables	33.64	32.4
	(b) Other financial liabilities	1.36	
	(c) Other current liabilities	0.80	0.9
	(d) Provisions	2.58	5.6
	(e) Current tax liabilities (Net)		
	Sub Total - Liabilities	38.38	39.0
	TOTAL EQUITY AND LIABILITIES	1,220.00	1,210.2









MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544

_	CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH Particulars		r Ended
	raruculais	30-Sep-21	30-Sep-20
		(Unaudited)	(Unaudited)
	CALCULAR ON THE CALCULAR ACTION THE CALCULAR A	(Chaudited)	(Chauditeu)
A	CASH FLOW FROM OPERATING ACTIVITIES	12.46	(42.47)
	Net Profit before tax and Extraordinary Items	12.40	(42.47)
	Adjustment for:	* 0 ((00
	Depreciation / Amortisation	5.94	6.88
	Interest Income	(7.28)	(0.59)
	Reclassification of remeasurement of employee benefits	1.32	(0.95)
	Interest Expenses	1.52	7.06
	Net loss on sale of Investment		0.06
	Investment Expenses	0.02	0.03
	Sundry balance Off	0.35	(0.00)
	Operating Profit before Working Capital Changes	14.33	(29.99)
	Adjustments for Working Capital Changes		
	Increase/Decrease in Assets	(22.30)	(60.83)
	Changes in Inventories	(274.87)	(1,012.83
	Increase/Decrease Trade Receivable	(226.38)	1,224.60
	Increase/Decrease Trade payables	1.20	(37.79
	Increase/Decrease in other financial and non-financial liabilities	1.36	(7.60
	Increase/Decrease in Liabilities	(0.12)	(76.18
	Changes in Provision	(3.07)	0.63
	Cash Generated from Operations	(509.85)	0.01
	Direct taxes paid / (refund)	(16.34)	(14.50
	Net Cash from Operating Activities	(526.19)	(14.49
В	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of Fixed Assets including Capital Work in Progress		
	(Loss) on Sale of Investment		(0.06
	Investment Expenses	(0.02)	(0.03
	Interest Received	7.43	0.60
	Net Cash Used in Investing Activity	7.41	0.51
C	CASH FLOW FROM FINANCING ACTIVITIES		
	Net (Decrease)/ Increase in Short Term Borrowings		50.27
	Interest Paid	(1.52)	(7.06
	Net Cash Used in Financing Activity	(1.52)	
	NET CHANGES IN CASH & CASH EQUIVALENTS (A+B+C)	(520.30)	29.23
	OPENING BALANCE OF CASH & CASH EQUIVALENTS	819.72	55.31
	CLOSING BALANCE OF CASH & CASH EQUIVALENTS	299.42	84.54
		520.30	(29.23









MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



Notes:

- 1) The above unaudited financial results of the Company for the quarter and half year ended September 30, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 13.11.2021.
- The Unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- 4) The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results including credit reports and related information, economic forecasts, market value of certain investments etc. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
- The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 6) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

FOR TRIOCHEM PRODUCTS LIMITED

RAMU S. DEORA DIRECTOR & CEO

DIN: 00312369

Place: Mumbai

Dated: 13th November, 2021





MANUFACTURERS OF ETHICAL PHARMACEUTICAL PRODUCTS

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra,

PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2202 4657

E-mall: info@amphray.com Website: www.triochemproducts.com

Corporate Identity Number: L24249MH1972PLC015544



TRIOCHEM PRODUCTS LIMITED

Registered Office: Sambava Chambers, 4th Floor, Sir P. M. Road, Fort. Mumbai - 400 001 website: www.triochemproducts.com

CIN: L24249MH1972PLC015544

(Rs. in lakhs) Except EPS

RACT OF STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTE	ER AND HAL	F YEAR ENDE	D 30TH SEI	PTEMBER, 20	21	
Particulars						For the
	30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	Year Ended
						31-Mar-21
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from operations	337.27	18.19	230.24	355.46	231.54	1,407.22
Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items)	27.66	(15.21)	(7.16)	12.46	(42.47)	(58.11)
Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	27.66	(15.21)	(7.16)	12.46	(42.47)	(58.11)
Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items)	20.36	(10.93)	(5.43)	9.44	(31.93)	
	(0.27)	1.26	(0.79)	0.99	(0.71)	(1.75
tax) and other Comprehensive Income (after tax)]						
Equity share capital (Face value Rs.10/- per share)	24.50	24.50	24.50	24.50	24.50	24.50
Other Equity						1,146.69
Earnings per share (of Rs.10/- each) (for continuing and discontinued operations)						
a) Basic (not annualized)	8.31	(4.46)	(2.22)	3.85	(13.03)	
b) Diluted (not annualized)	8.31	(4.46)	(2.22)	3.85	(13.03)	(18.25)
	Particulars Total Income from operations Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items) Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] Equity share capital (Face value Rs.10/- per share) Other Equity Earnings per share (of Rs.10/- each) (for continuing and discontinued operations) a) Basic (not annualized)	Particulars Particulars Unaudited Total Income from operations Net Profit / (Loss) for the period (before Tax. Exceptional and / or Extraordinary items) 27.66 Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items) 27.66 Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) 20.36 Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items) 20.36 Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive Income (after tax)] Equity share capital (Face value Rs.10/- per share) Other Equity Earnings per share (of Rs.10/- each) (for continuing and discontinued operations) a) Basic (not annualized) 8.31	Particulars Quarter Ender 30-Sep-21 30-Jun-21 Unaudited Unaudite	Particulars Quarter Ended 30-Sep-21 30-Jun-21 30-Sep-20	Particulars Quarter Ended Half Yea 30-Sep-21 30-Jun-21 30-Sep-20 30-Sep-21 30-Sep-20 30-Sep-21 30-Jun-21 30-Sep-20 30-Sep-21 30-Sep-20 30-Sep-21 30-Sep-20 30-Sep-21 30-Sep-20 30-Sep-21 30-Sep-20 30-Sep-21 30-Sep-20 30-Sep-20	30-Sep-21 30-Jun-21 30-Sep-20 30-Sep-21 30-Sep-20 30-Sep-21 30-Sep-20

Notes:

- The above unaudited financial results of the Company for the quarter and half year ended September 30, 2021 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 13.11.2021.
- 2) The Unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 (the Act), as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The company has adopted Ind AS 116 effective period beginning from April 01, 2019. The effect of adoption of Ind AS 116 on the financial results is insignificant.
- 4) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
- The Company has considered the possible effects that may arise out of the still unfolding COVID-19 pandemic on the carrying amounts of property, plant & equipment, inventories, trade receivables, etc. For this purpose, the Company has considered internal and external sources of information up to the date of approval of the Financial Results including credit reports and related information, economic forecasts, market value of certain investments etc. Based on the current estimates, the Company does not expect any significant impact on such carrying values. The impact of COVID-19 on the Company's financial statements may differ from that estimated as at the date of approval of Financial Results.
- 6) The Indian Parliament has approved the Code on Social Security, 2020 which would impact the contributions by the company towards Provident Fund and Gratuity. The Ministry of Labour and Employment has released draft rules for the Code on Social Security, 2020 on November 13, 2020, and has invited suggestions from stakeholders which are under active consideration by the Ministry. The Company will assess the impact and its evaluation once the subject rules are notified and will give appropriate impact in its financial statements in the period in which, the Code becomes effective and the related rules to determine the financial impact are published.
- 7) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.
- 8) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of consolidated financial results are available on the Stock Exchange website, www.bseindia.com and on the Company's website www.triochemproducts.com

FOR TRIOCHEM PRODUCTS LIMITED

Place: Mumbai

Dated: 13th November, 2021

DIRECTOR & CEO DIN: 00312369



Date & Time of Download: 13/11/2021 15:03:47

BSE ACKNOWLEDGEMENT

Acknowledgement Number	3421953				
Date and Time of Submission	11/13/2021 3:03:38 PM				
Scripcode and Company Name	512101 - TRIOCHEM PRODUCTS LTD.				
Subject / Compliance Regulation	Board Meeting Outcome for Outcome Of The Board - Pursuant To Regulation 30 And 33 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulation, 2015				
Submitted By	Puran Jaykisan Parmar				
Designation	Designated Officer for Filing				

Disclaimer: - Contents of filings has not been verified at the time of submission.